Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Vascular Biogenics Ltd. (VBLT)

1.63   0.02 (1.24%) 07-02 16:17
Open: 1.6138 Pre. Close: 1.61
High: 1.64 Low: 1.58
Volume: 89,527 Market Cap: 113(M)
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.64 - 1.65 1.65 - 1.65
Low: 1.56 - 1.57 1.57 - 1.58
Close: 1.62 - 1.63 1.63 - 1.64

Technical analysis

as of: 2022-07-01 4:25:59 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.28     One year: 2.67
Support: Support1: 1.5    Support2: 1.21
Resistance: Resistance1: 1.96    Resistance2: 2.28
Pivot: 1.44
Moving Average: MA(5): 1.59     MA(20): 1.46
MA(100): 1.51     MA(250): 1.85
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 84.7     %D(3): 84
RSI: RSI(14): 59.6
52-week: High: 2.58  Low: 1.1
Average Vol(K): 3-Month: 178 (K)  10-Days: 109 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VBLT ] has closed below upper band by 9.7%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 02 Jul 2022
Vascular Biogenics (NASDAQ:VBLT) Shares Pass Above Fifty Day Moving Average of $1.54 - Defense World

Sat, 02 Jul 2022
Vascular Biogenics (NASDAQ:VBLT) Now Covered by StockNews.com - MarketBeat

Thu, 30 Jun 2022
VBL Therapeutics to Participat - GuruFocus.com

Thu, 16 Jun 2022
Vascular Biogenics (NASDAQ:VBLT) Coverage Initiated by Analysts at StockNews.com - Defense World

Fri, 10 Jun 2022
Vascular Biogenics (NASDAQ:VBLT) Upgraded by Zacks Investment Research to Hold - Defense World

Fri, 03 Jun 2022
Weekly Analysts' Ratings Changes for Vascular Biogenics (VBLT) - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 69 (M)
% Held by Insiders 4.641e+007 (%)
% Held by Institutions 23.9 (%)
Shares Short 557 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.874e+007
EPS Est Next Qtl -0.19
EPS Est This Year -0.75
EPS Est Next Year -0.78
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 905.7
Return on Equity (ttm) -35.3
Qtrly Rev. Growth 768000
Gross Profit (p.s.) -3.83
Sales Per Share -63.86
EBITDA (p.s.) 350435
Qtrly Earnings Growth -0.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -25 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 2.37

Stock Dividends

Dividend 0
Forward Dividend 688030
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.